Intra-Cellular Therapies (NASDAQ:ITCI) has been assigned a $21.00 price target by analysts at JMP Securities in a research note issued to investors on Tuesday, TipRanks reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. JMP Securities’ price target would indicate a potential upside of 106.08% from the company’s current price.
Other equities research analysts have also recently issued research reports about the company. Cowen restated a “buy” rating and issued a $28.00 target price on shares of Intra-Cellular Therapies in a research note on Monday, July 8th. Royal Bank of Canada set a $26.00 price target on shares of Intra-Cellular Therapies and gave the stock a “buy” rating in a research note on Wednesday, August 7th. BidaskClub raised shares of Intra-Cellular Therapies from a “strong sell” rating to a “sell” rating in a research note on Saturday. Zacks Investment Research lowered shares of Intra-Cellular Therapies from a “buy” rating to a “hold” rating in a research report on Thursday, July 18th. Finally, ValuEngine lowered shares of Intra-Cellular Therapies from a “buy” rating to a “hold” rating in a research report on Wednesday, September 4th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the company. Intra-Cellular Therapies currently has an average rating of “Buy” and an average price target of $23.63.
Shares of ITCI traded down $0.21 during midday trading on Tuesday, hitting $10.19. The stock had a trading volume of 827,927 shares, compared to its average volume of 657,422. The firm has a market cap of $564.67 million, a price-to-earnings ratio of -3.59 and a beta of 1.19. The company has a 50 day simple moving average of $8.84 and a two-hundred day simple moving average of $11.76. Intra-Cellular Therapies has a twelve month low of $7.41 and a twelve month high of $23.62. The company has a debt-to-equity ratio of 0.08, a current ratio of 8.86 and a quick ratio of 8.86.
In related news, Director Christopher D. Alafi acquired 485,000 shares of the business’s stock in a transaction dated Tuesday, September 10th. The stock was bought at an average price of $10.26 per share, with a total value of $4,976,100.00. Following the acquisition, the director now owns 341,223 shares in the company, valued at approximately $3,500,947.98. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Christopher D. Alafi bought 125,000 shares of the firm’s stock in a transaction that occurred on Friday, August 30th. The stock was purchased at an average cost of $8.52 per share, with a total value of $1,065,000.00. Following the completion of the purchase, the director now directly owns 341,223 shares of the company’s stock, valued at approximately $2,907,219.96. The disclosure for this purchase can be found here. Corporate insiders own 18.20% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. FMR LLC lifted its stake in Intra-Cellular Therapies by 0.7% in the first quarter. FMR LLC now owns 8,267,510 shares of the biopharmaceutical company’s stock valued at $100,698,000 after acquiring an additional 58,561 shares during the last quarter. BlackRock Inc. increased its stake in shares of Intra-Cellular Therapies by 2.2% during the 2nd quarter. BlackRock Inc. now owns 3,933,274 shares of the biopharmaceutical company’s stock worth $51,055,000 after purchasing an additional 84,063 shares during the last quarter. Wasatch Advisors Inc. raised its holdings in shares of Intra-Cellular Therapies by 19.0% in the 1st quarter. Wasatch Advisors Inc. now owns 2,361,619 shares of the biopharmaceutical company’s stock valued at $28,765,000 after purchasing an additional 377,561 shares during the period. Dimensional Fund Advisors LP raised its holdings in shares of Intra-Cellular Therapies by 1.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,444,223 shares of the biopharmaceutical company’s stock valued at $16,450,000 after purchasing an additional 24,335 shares during the period. Finally, Schroder Investment Management Group lifted its stake in Intra-Cellular Therapies by 5.6% in the 2nd quarter. Schroder Investment Management Group now owns 1,430,469 shares of the biopharmaceutical company’s stock valued at $18,567,000 after purchasing an additional 75,757 shares during the last quarter. 68.97% of the stock is currently owned by hedge funds and other institutional investors.
Intra-Cellular Therapies Company Profile
Intra-Cellular Therapies, Inc, a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative disorders. The company is developing its lead drug candidate, lumateperone for the treatment of schizophrenia, bipolar disorder, behavioral disturbances associated with dementia, autism, and other CNS diseases.
See Also: Total Return
Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.